Multidisciplinary approach of colorectal cancer liver metastases

Giammaria Fiorentini, Donatella Sarti, Camillo Aliberti, Riccardo Carandina, Andrea Mambrini, Stefano Guadagni

Abstract

Large bowel cancer is a worldwide public health challenge. More than one third of patients present an advanced stage of disease at diagnosis and the liver is the most common site of metastases. Selection criteria for early diagnosis, chemotherapy and surgery have been recently expanded. The definition of resectability remains unclear. The presence of metastases is the most significant prognostic factor. For this reason the surgical resection of hepatic metastases is the leading treatment. The most appropriate resection approach remains to be defined. The two step and simultaneous resection processes of both primary and metastases have comparable survival long-term outcomes. The advent of targeted biological chemotherapeutic agents and the development of loco-regional therapies (chemoembolization, thermal ablation, arterial infusion chemotherapy) contribute to extend favorable results. Standardized evidence-based protocols are missing, hence optimal management of hepatic metastases should be single patient tailored and decided by a multidisciplinary team. This article reviews the outcomes of resection, systemic and loco-regional therapies of liver metastases originating from large bowel cancer.

Key words: Colorectal cancer; Chemoembolization; Liver metastases; Hepatic resection; Colorectal cancer liver metastases; Chemotherapy; Arterial infusion chemotherapy; Radioembolization

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Improvements of colorectal cancer liver...
metastases (CRC-LM) treatment allows the down-staging of several patients. There is currently no agreement in the correct sequence of surgical resection of the primary cancer and metastatic disease. Surgical resection can be performed if the complete removal of cancer is achievable, leaving an adequate normal liver tissue. Neoadjuvant chemotherapy is widely accepted as primary therapy. Chemotherapy may lead to disease regression for unresectable CRC-LM, allowing resection and cure. The application of loco-regional therapies is increasing. They are recommended as third-line treatment for unresectable CRC-LM and have a palliative intent.

**INTRODUCTION**

Colorectal cancer (CRC) is an increasing global health issue\(^1,2\) It is the most common gastro-intestinal tumor and the third most frequently diagnosed malignancy worldwide. It has a mortality rate of up to 10%\(^1,2\). Most recent epidemiological data show more than 1.4 million newly diagnosed CRC each year\(^\[3\]\). The liver is the most common site of CRC metastases with an incidence of 15%-20% at diagnosis. CRC patients have a > 50% probability of liver metastases development\(^\[4,5\]\). The majority of CRC liver metastases (CRC-LM) were defined not resectable in the past century. Surgery methods are considerably improved nowadays, resulting in cure or survival increase. CRC-LM resection rates are also increased\(^6\). Recent updating of resectability criteria of CRC-LM considerably improves outcomes, resulting in 5 and 10-year survival rates of 40% and 25% respectively\(^6,5\).

Notwithstanding these good outcomes, the recurrence rate one year after metastasis resection is 30% and a recent study on CRC-LM survival after resection shows a 5-year survival of 16%-71%\(^7\).

Neoadjuvant chemotherapy allow initially unresectable CRC-LM patients to have long term survival similar to those of resectable patients\(^8-12\)\). Chemotherapy efficacy, in terms of tumor reduction, is strongly correlated to resectability\(^10-13\). For this reason, chemotherapy associated to biological agents is increasingly used as resectability conversion of CRC-LM from unresectable to resectable. This method can efficiently increase downsizing rates\(^14,15\).

Candidate selection for resection is difficult and several CRC-LM patients are never referred to hepatobiliary multidisciplinary group\(^10,12\). For this reason CRC-LM patients need a multidisciplinary team for treatment decision. This team should include specialists from different disciplines: Oncology, surgery, radiology and radiotherapy. The purpose of this review is to examine the current management of CRC-LM, in order to better define potential advantages and limitations of the several available treatments.

**PERIOPERATIVE EVALUATION**

The perioperative evaluation of a patient's global health and liver function is essential to reduce postoperative complications. A dedicated multidisciplinary team should assess co-morbidities and patient's performance status in order to decide a future treatment plan. Complete blood examination should be performed before surgery, to assess liver function [alanine aminotransferase (ALT), glutamic-oxalacetic transaminase (AST)], coagulation profile, bilirubin, creatinine and tumor markers, such as carcinoembryonic antigen (CEA).

Exclusion criteria for surgery include several factors to guarantee patient safety. They include advanced age, male gender, low serum albumin, presence of liver disease (hepatitis or alcoholic hepatitis), ascites, kidney or cardiologic impairment, bleeding syndromes, and chronic obstructive pulmonary disease\(^16-18\). Morbidity and mortality after liver resection is often due to inadequate function of remnant liver, leading to liver failure. Morbidity and mortality rates are around 61% and 11%, respectively\(^16,17\). The remnant liver cannot sustain metabolic, synthetic, and detoxifying functions if reduced below a critical liver volume\(^19\). Liver volume is not the best index for liver functionality assessment\(^16-20\). Patients with concomitant liver disease may have impaired liver regeneration capacity due to cirrhosis, steatosis, or jaundice obstruction\(^20\).

Most chemotherapeutic agents (5-fluorouracil, irinotecan, oxaliplatin) can result in hepatic damage and modification of liver regeneration\(^21-23\). Morbidity and mortality after liver resection may be improved by measuring the intake of 99mTc mebrofenin of tumor-free liver in a pre-operative setting, in order to assess the risk of liver failure and liver failure-related mortality after partial liver resection\(^24\).

During liver regeneration induced by partial hepatectomy, normally quiescent hepatocytes start to replicate in order to restore the original liver. Several genes are involved in liver regeneration, including cytokine, growth factor and metabolic genes\(^25\). Several studies show that recurrence and progression are directly proportional to the amount of liver resected\(^22,23\).

Neoadjuvant chemotherapy may induce hepatic changes, such as steatohepatitis, hepatic sinusoidal obstruction and periportal inflammation, negatively affecting patient outcome\(^20,24\) and increasing the risk of liver failure and death after major liver resection. A normal liver can bear an extensive resection. Severely compromised livers, on the contrary, cannot tolerate even a minor hepatectomy\(^8,9,19\).

For this reason, monitoring the functionality of surrounding tumor-free liver needs to be highly considered for selection of surgical method.
CRC-LM radiological study is necessary for assessment of surgical resectability. This can be performed using any of these main radiological methods: Magnetic resonance imaging (MRI), computed tomography (CT) and positron emission tomography (PET) scan. Liver metastases can be detected as hypoattenuating lesions, when using contrast-enhanced normal or multidetector CT scans with a sensitivity rate of 85% and 90%, respectively. MRI performed with liver-specific contrast agents has > 90% sensitivity in cases of underlying liver disease (steatosis, cirrhosis) or very small lesions (< 1 cm). For this reason MRI is better than CT for metastasis detection.

Specificity of CT, MRI and PET is very high: 95%, 93%, and 97% respectively. PET scan is useful to obtain whole body map, to identify extrahepatic disease (EHD) and to assess resectability. A recent study showed that the FDG PET scan is the best radiological modality for detecting CRC-LM. It can have high false negative rates in patients recently treated with chemotherapy. The association of CT to FDG PET scans is highly recommended because it improves the sensitivity up to 97%. Nowadays, also intraoperative ultrasound (IOUS) is a mandatory surgical tool to confirm preoperative investigations by CT or MRI and for detection of missed lesions.

CRITERIA FOR RESECTABILITY
The preferred therapy for CRC-LM is surgery, providing up to 50% survival at five-years. Patient selection criteria for resectability are not standardized and still controversial in clinical practice. The American Hepato-Pancreato-Biliary Association (AHPBA) consensus on definition of resectability is currently accepted by most liver surgeons. Main CRC-LM resection criteria of AHPBA are: Presence of disease confined to the liver as identified after surgery of primitive cancer; disease in a single hepatic lobe; < 3 nodules; the largest size of nodules < 5 cm in diameter; margin FLR > 1 cm. According to these criteria, however, less than 10% of patients would be indicated for resection.

The classification of resectable disease is broader nowadays, increasing the number of resections. Current guidelines generally agree that surgery should be performed for liver metastases only, but hepatectomy and resections of concomitant extrahepatic disease are considered. The remaining liver must be undamaged and at least 20% or 25% of the whole hepatic volume, and have a full functional vascular and biliary in- and out-flow. In this case also multiple resection can be performed. The survival advantage of repeated resection is close to that after the surgery of primary hepatic disease. Hepatic resection safety depends on: Age of patients, performance score, and concomitant hepatic impairments. Resection is contraindicated when the following are observed: Non resectable extra hepatic tumor; wide involvement of parenchyma; or patient’s poor general conditions.

Possible prognostic factors of resection outcome of CRC-LM are: Age, sex, synchronous or metachronous hepatic metastases, tumor size, number and distribution of LM, primary tumor stage, extrahepatic distant metastases, surgical margin, type of primary hepatic tumor surgery and previous tumor pharmacological therapy, levels of tumor markers.

Fong et al report data from 1001 CRC-LM patients who were candidates for resection. These data led to the identification of seven criteria for worse prognosis prediction after resection. Five of these criteria are actually used for the Clinical Risk Score (CRS) that is a preoperative scoring system. These criteria are: Disease-free interval from primary to metastases < 12 mo; largest hepatic tumor > 5 cm in diameter; node-positivity; number of lesions > 1; and CA 19-9 > 200 ng/mL. Positive prognosis after surgery corresponds to a score < 2. Scores of 3-4 indicate that patients are candidates for resection followed by adjuvant therapy. Prognosis is poor when the score is five. The appropriateness of CRS is proved. CRS can predict patients’ response and OS.

A new method has been recently introduced in the CRC-LM resectability criteria assessment. Resection criteria are different. They depend less on the size, number, and location of the metastases. They give more importance to the volume and function of the future liver remnant (FLR), which should be > 25% estimated normal liver parenchyma or 30% in the presence of impaired liver function. Metastases are considered resectable if the excision of all metastatic lesions can be obtained with an adequate FLR and the presence of EHD is currently no longer considered as a contraindication. The new requirements for LM resection are: R0 resection achievement of intrahepatic and extra hepatic disease; adequate FRL; and > 2 adjacent liver segments to be spared with blood and bile inflow and outflow preservation.

TIMING OF COLON AND LIVER RESECTION
The best sequence and timing of CRC-LM resection is still under debate and many options are available. The use of up front chemotherapy is increasing. Strong evidence is missing and there are currently no randomized controlled trials comparing the different approaches.

The classic surgical method is “primary first”, whose suggested sequence is to firstly resect the primary CRC, then to administer the chemotherapy and after 3-6 mo to eventually resect the LM. This approach is indicated for patients with advanced or symptomatic CRC, important comorbidities, or inadequate FLR. In cases of advanced CRC, indeed, the chemotherapy may be associated with high complication rates and the insufficiency of disease progression may lead to unresectability. Any delay correlated to complications during surgery of CRC may also increase the risk of progression occurrence for some patients. A possible benefit of this method can be
the possibility to identify previously occult LM that may become visible during adjuvant chemotherapy. This allows avoidance of the morbidity of a liver resection.

Another surgical method is the “synchronous resection of LM and primary CRC”. This approach can avoid delays in chemotherapy treatment that can be started earlier if no complications occur after surgery. The possible disadvantage of this method is the increased postoperative morbidity and mortality because of infection resulting from bacterial contamination of the surgical field[36]. For this reason this approach is indicated for patients who can tolerate long operative times[85].

The third available surgical method is the “alternative staged liver-first” approach that firstly resect the LM, then administer 3-6 cycles of chemotherapy, and at last resect the primary CRC. Adjuvant chemotherapy can be administered in between both procedures. Recent data report that this method is indicated for selected patients with advanced CRC-LM, and when neo-adjuvant and adjuvant chemotherapy may have better results[9,12].

### CHEMOTHERAPY FOR RESECTABLE CRC-LM

#### Neo-adjuvant chemotherapy

The utility of neoadjuvant chemotherapy for CRC-LM is unclear even if there is the tendency to use it frequently[15]. There are many advantages of neo-adjuvant treatment such as increasing tumor sensitivity, downstaging large or multiple liver lesions, increasing resectability, and treating micrometastases[8,9,11]. This therapy also allows better planning for the date of surgical resection.

On the other hand, neo-adjuvant chemotherapy can delay surgical treatment, which may be detrimental for patients, increasing the risk of disease progression[12,15]. This chemotherapy can also induce liver toxicity, such as steatohepatitis, increasing postoperative mortality. It can also mask metastases on preoperative imaging, as is observed in 5%-25% of cases[42].

Perioperative chemotherapy is widely used for patients with unresectable disease (Table 1 and Figure 1) with the purpose of reducing disease progression, which occurs in 50%-70% of patients after surgery[33]. A multicentre randomized trial compared surgery alone with perioperative chemotherapy (6 cycles of preoperative and post operative FOLFOX4) in 364 unresectable CRC-LM patients. The results of this study showed no significant differences in five-year OS for the two groups; nevertheless, progression-free survival (PFS) increased by 7.3% at 3 years in the perioperative chemotherapy group[43]. The rate of post-operative complications is also increased and is directly proportional to the length of therapy. For this reason, it is suggested that only 6 cycles of chemotherapy for no longer than 3 mo should be performed, in order to reduce toxicity[28], especially for patients who need a major hepatectomy[44].

Patients with more than 3 lesions, and tumor diameter greater than 3 cm are clearly indicated for this treatment. The surgery of lesions should be done 4-8 wk after the neo-adjuvant chemotherapy. In summary, the advantages of neo-adjuvant chemotherapy outnumber the disadvantages, and we are in favor of its utilization.

#### Adjuvant chemotherapy

The ultimate dilemma after complete CRC-LM resection is the rate of recurrence that is reported as high as 60% after complete surgical excision. Several studies show the benefits of adjuvant therapy such as FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin), resulting in longer disease-free-survival (DFS)[45] than liver resection alone.

Adjuvant chemotherapy also increases OS when compared to surgery alone, even if the difference is not statistically significant[46,47]. The classic adjuvant chemotherapeutic drugs are: 5-fluorouracil/leucovorin (5-FU/LV), capetibatib, oxaliplatin and irinotecan[47]. New molecular-targeted agents are now available. They include anti-angiogenic drugs (bevacizumab, regorafenib and aflibercept) and anti-

---

### Table 1  Recommendations for perioperative and conversion therapy (adapted from ESMO 2016[1,2,3])

| Recommendation                                                                 |
|-------------------------------------------------------------------------------|
| **Perioperative treatment**                                                    |
| It is defined by technical criteria for resection and prognostic considerations|
| It may not be necessary in patients with clearly resectable disease and favourable prognosis, in this case upfront resection is justified |
| It should administer FOLFOX or CAPOX to patients with resectable disease and unclear (probably unfavourable) |
| Targeted agents should not be used in resectable patients with prognostic indication for perioperative treatment |
| It should be considered when prognostic and resectability criteria are unclearly defined, and in patients with synchronous onset of metastases |
| Adjuvant chemotherapy is not strongly indicated for patients with favourable oncological and surgical criteria, who did not receive any neoadjuvant chemotherapy |
| Adjuvant chemotherapy is indicated for patients with unfavourable criteria |
| Adjuvant treatment with FOLFOX or CAPOX is recommended for patients who have not received any previous chemotherapy, unless patients already received oxaliplatin-based adjuvant chemotherapy |
| The choice of chemotherapy type should consider patients’ clinical conditions and therapy preferences |

| **Conversion therapy**                                                          |
| A chemotherapy regimen leading to high response rates and/or a large tumour shrinkage is recommended for potentially resectable patients |
| The best drug combination to use is still not clear because only few trials have addressed this issue: |
| RAS wild-type patients may benefit from a cytotoxic doublet plus an epidermal growth factor receptors agents antibody (best benefit/risk), and from the combination of FOLFOXIRI plus bevacizumab and, to a lesser extent, from a cytotoxic doublet plus bevacizumab |
| RAS mutant patients may benefit from a cytotoxic doublet plus bevacizumab or FOLFOXIRI plus bevacizumab |
| Patients must be re-evaluated regularly (every 2-3 mo) to prevent the overtreatment of resectable patients |

---

Fiorentini G et al. Treatment of colorectal cancer liver metastasis...
epidermal growth factor receptors agents (anti-EGFR), such as cetuximab and panitumumab. These agents are widely used as adjuvant treatment without any evidence of clinical benefit [48].

Adjuvant chemotherapy after metastasectomy is generally recommended by clinicians, even if the best regimen protocol is still unclear, and should be considered in a patient dependent manner [24]. There, efficacy of adjuvant chemotherapy on OS for resectable CRC-LM is still under discussion [45]. The National Comprehensive Cancer Network (NCCN) guidelines suggests the use of more than one chemotherapy line [48]. Most study agree that 5-FU/LV with or without oxaliplatin should always be used as first-line [47]. More recently, however, the use of combination therapy is increasing, and several combinations have emerged. A recent study on FOLFIRI (5-FU/LV and irinotecan) vs 5FU/LV after R0 (complete resection) of CRC-LM does not report any difference in OS and median DFS. FOLFIRI improves DFS, but causes more frequent grade 3/4 toxic adverse events (47% vs 30%) [49].

We suggest the use of adjuvant chemotherapy in patients with multiple lesions that are found in more than 3 liver segments, where the surgery, even if radical, may not be able to remove undetected tumor deposits.

**CHEMOTHERAPY FOR UNRESECTABLE CRC-LM**

Patients with unresectable CRC-LM from diagnosis should receive chemotherapy in order to downstage the disease and allow the surgery (Figure 1 and Table 2).

About 70% of patients with CRLM are unresectable at diagnosis [4]. They have a complicated disease, often requiring a combination of loco-regional therapy (chemoembolization, hepatic arterial infusion, ablation or radiation).

Perioperative chemotherapy is widely used also for unresectable CRC-LM, even if there is no proof of OS improvement [50]. Systemic chemotherapy remains the first-line therapy. FOLFOXIRI followed by surgical resection has a 70.4% response rate, and 19% of patients obtain R0. OS at 5 and 8 years are 42% and 33% respectively, and 29% of patients are disease free at 5 years [51].

Downstaging of unresectable CRC-LM ranges from 5% to 38%. This is due to multiple factors including disease extension, type and duration of chemotherapy [51]. The purpose of the "conversion chemotherapy" in unresectable CRC-LM patients is to convert their disease to resectable, and is often the first line treatment. Standard regimens include FOLFIRI or FOLFOX that induce downstaging in 7%-40% of patients [52]. Giacchetti’s group reports that FOLFOX reduces the LM dimension by more than 50% in 59% of non-resectable CRC-LM, resulting in 38% of CR [52]. FOLFOXIRI allows 36% of R0 in LM patients [53]. The METHEP trial reports that FOLFIRINOX seems to be better therapy for CRC-LM than the others, bringing to resection 67% of cases with a survival > 48 mo. These results confirm that OS is greater for patients after R0 or...
Table 2 Conversion rates in colorectal cancer liver metastases after perioperative chemotherapy

| Trial name       | Chemotherapy type                                      | Control  | n    | KRAS status | Overall response | Conversion to R0 resection |
|------------------|--------------------------------------------------------|----------|------|-------------|------------------|---------------------------|
| BEAT[61]         | FOLFOX/XELOX/FOLFIRI or fluoropyrimidines + bevacizumab| Placebo  | 1914 | Not selected| NA               | 11.80%                    |
| First BEAT[62]   | FOLFOX/XELOX + bevacizumab                             | Placebo  | 1914 | Not selected| 38%              | 6.3% vs 4.9%              |
| OPUS[76]         | FOLFOX + cetuximab                                     | FOLFOX   | 233  | Wild type   | 61% vs 37%       | 9% vs 2.4%                |
| POCHER[72]       | Chr IFLO + cetuximab                                   | FOLFOX   | 43   | Wild type   | 79%              | 60%                       |
| PRIME[73]        | FOLFOX + panitumumab                                   | FOLFOX   | 591  | Wild type   | 57% vs 45%       | 31% vs 22%                |
| CELIM[74]        | FOLFOX6 + cetuximab                                    | FOLFIRI  | 106  | Wild type   | 68% vs 57%       | 45%                       |
| BOXER[75]        | CAPOX + bevacizum                                      | FOLFIRI  | 47   | Not selected| 78%              | 40%                       |
| Loupakis et al[76]| FOLFOXIRI + bevacizum                                  | FOLFIRI  | 508  | Not selected| 65% vs 53%       | 15% vs 12%                |
| Ye et al[77]     | FOLFIRI + cetuximab                                    | FOLFIRI  | 177  | Wild type   | 57% vs 29%       | 26% vs 7%                 |
| CRISTAL[78]      | FOLFIRI + cetuximab                                    | FOLFIRI  | 599  | Wild type   | 47% vs 39%       | 16%                       |
| OLIVIA[79]       | FOLFOXIRI + bevacizum                                  | FOLFIRI  | 80   | Not selected| 81% vs 62%       | 61% vs 49%                |

CAPOX, XELOX: Capecitabine-oxaliplatin; NA: Not available; Chr IFLO: Chronomodulated irinotecan, 5-fluorouracil, leucovorin, and oxalipaltin; FOLFIRI: 5-fluorouracil, leucovorin and irinotecan; FOLFOX: 5-fluorouracil, leucovorin, oxalipaltin and irinotecan.

R1 surgery, 65.2 mo vs 18.3 mo of not-operated or R2 patients[8].

The use of bevacizumab is increasing for unresectable CRC-LM[55,66], even if the benefits are extremely limited. A slight gain in response rate is observed when bevacizumab is associated with FOLFOXIRI as first line chemotherapy. The association of bevacizumab to first and second line chemotherapy for CRC-LM improves PFS[57-60] and OS in some studies[59,60]. Available data on the efficacy of bevacizumab associated to perioperative chemotherapy are limited. This may be due to concerns about possible complications in wound healing after resection[61,62]. The Bevacizumab Expanded Access Trial reports good feasibility of LM surgery after first-line chemotherapy associated to bevacizumab, resulting in resection rates of 11.8% and 6% of R0[63]. Bevacizumab association with FOLFOX, however, obtains higher resection rates (16.1%) than with FOLFIRI (9.7%), and higher R0 (6.3%) than FOLFOX plus placebo (4.9%) (P = 0.24)[62]. Neoadjuvant capecitabine and oxaliplatin (CAPOX) plus bevacizumab resulted in 40% of CRC-LM resectability conversion[63]. Loupakis et al[55] report 64% of tumor response and 15% of rate of resection of CRC-LM after FOLFIRI plus bevacizumab, vs 53% and 12% respectively after FOLFIRI/bevacizumab.

Transarterial chemoembolization with irinotecan combined with FOLFOX plus bevacizumab chemotherapy results in a response rate of 78%, and allows resection of 35% of non resectable CRC-LM, offering a new care option to these patients[80].

A recent report by Stremitzer et al[63] shows that mutated BRAF/RAS are correlated to a poor outcome after CRC-LM surgery. This is in agreement with the results of other 3 studies[66-69]. These important evidences support the application of newer methods for the therapy of liver metastases, associating biological molecular aspects (biological resectability) to the other clinical and pathological indexes for the selection of good surgical candidates and the prediction of their outcomes.

Anti-EFGR agents such as cetuximab and panitumumab are effective alone as well as in association with chemotherapy in CRC-LM that are RAS (both KRAS and NRAS) wild type[69]. Some randomized trials report the effects of cetuximab for the therapy of unresectable CRC-LM. The OPUS trial[70] showed that the association of FOLFOX-4 plus cetuximab as up front therapy doubled R0 (4.7%). The CRYSTAL study[71] showed that the association of FOLFIRI plus cetuximab as up front therapy increased the R0 resection rate from 3.7% to 7.0%. The CELIM trial[71] reported that neoadjuvant treatment with FOLFIRI plus cetuximab or FOLFOX6 resulted in 34% of R0 resections. Other studies also report that chemotherapy containing cetuximab significantly improves R0 in unresectable CRC-LM with KRAS wild-type[72,73]. There are differences in resection rates among the above studies. Overall response rate is in the range 60%-79%, however, resection rates after chemotherapy/cetuximab are very variable (Table 2). These discrepancies may be due to the fact that the resection rate is defined and determined by clinical conditions of the patients and not by specialist oncologists in CRYSTAL and OPUS studies. Resection evaluation is done by a multidisciplinary team in the other trials.

The COIN[74] and NORDIC [75] trials report no advantage for the association of oxaliplatin based chemotherapy/cetuximab in first-line treatment of CRC-LM, independently from K-RAS status.

Resection rates of first-line FOLFIRI/panitumumab treatment of CRC-LM are 15% and 7% in the KRAS wild type (WT) and mutant groups respectively[76]. FOLFOX4 plus panitumumab results in 32% of R0 resections vs 28% of those receiving only FOLFOX4[77]. A post hoc analysis of the PRIME study on RAS WT (KRAS, NRAS) shows that panitumumab/FOLFOX can convert to resection 31% of initially unresectable CRC-LM patients and lead to 29% of R0 (Table 2)[78]. A further analysis of PRIME trial also shows that NRAS mutations are indications of non-response to panitumumab[77]. For this reason, it is extremely important to analyze other
types of mutations in the RAS gene to improve patient selection for anti EGFR therapy.

The OLIVIA trial studies FOLFOXIRI + bevacizumab vs mFOLFOX-6 + bevacizumab and reports an overall resection rate of 61% vs 49%, with R0 resection rates of 49% vs 23%.\(^{[79]}\)

In conclusion “biologically directed” chemotherapy reduces the number and size of unresectable lesions. It also allows rescue of 15%-35% of patients, bringing them to surgery. These therapies are increasingly used worldwide.

**EXTRA HEPATIC DISEASE**

Extra hepatic disease (EHD) has a poor prognosis.\(^{[28]}\) Most common sites of EHD from CRC are lymph nodes, lungs, peritoneum, brain and bone. EHD is currently no longer a contraindication to metastasis resection, and patients after surgery have longer DFS and five-year-survival rates compared to those receiving only chemotherapy.\(^{[5,6]}\)

OS after lymph node resection is different according to their site and number.\(^{[80]}\) Celiac or aorto-caval lymph node resections are associated with a worse outcome when compared to hepatic pedicle nodes, and mediastinal lymph nodes have a worse median survival than intra-thoracic ones.\(^{[80]}\) A high number of lymph nodes positive for metastases have also a poor outcome.\(^{[80]}\)

In conclusion, the treatment of EHD is substantially palliative, aiming to improve the quality of life.\(^{[81]}\)

**LOCO-REGIONAL THERAPIES**

Loco-regional therapies (Figure 2) are indicated for patients that are elderly, have a poor performance status, refusing surgery or chemotherapy, or refractory to chemotherapy. They also allow chemo-holidays with suspension of chemotherapy, and prolong the non-treatment period in between different chemotherapy lines. This reduces the treatment costs in respect to systemic chemotherapy.

In the last years new strategies have been developed in order to overcome several problems: High percentage of unresectable CRC-LM at diagnosis, high recurrence rates and presence of extensive disease. These methods increase the number of patients indicated for non surgical procedures.

Ablation techniques include radiofrequency ablation (RFA), Microwave ablation and external beam radiotherapy (EBRT). RFA is widely used and allows the application of extreme temperature to ablate the lesion with minimal toxicity (< 1%) in the surrounding liver tissue. RFA results in mortality and morbidity < 10% independently from the administration route.\(^{[82]}\) The “heat sink effect” is however a major disadvantage of RFA and may cause important hepatic or vascular injury. For this reason, RFA is not indicated for unresectable tumors, lesions near blood vessels or the diaphragm because of the high risk of perforation. Another disadvantage of RFA is the recurrence rate that is higher when the tumor is > 3 cm or when treatment is delivered percutaneously.\(^{[82,83]}\)

Microwave ablation uses high frequency microwave radiation to induce coagulation with necrosis of lesions. This method, however, is not well known and there are several concerns about its feasibility.\(^{[84]}\) Available data on this method show a 6% local recurrence rate.\(^{[85]}\)

Improvements in imaging methods have increased the use of EBRT,\(^{[86]}\) that, however, has a low therapeutic window, and toxicity is still a major issue. EBRT is safe (at 60 Gy) and effective for liver tumors in general and in selected patients.\(^{[87,88]}\)

**Intra-arterial therapies: Hepatic artery infusion**

Hepatic artery infusion (HAI) is indicated for patients with unresectable lesions when physicians want to associate an intra-arterial with an endovenous treatment.

The advantage of HAI is to minimize the toxicity to normal liver tissue, because the chemotherapeutic agents are injected directly to the tumor.\(^{[89]}\) Potential risks of this method are treatable complications related to catheter and pump placement, or life-threatening complications such as biliary sclerosis, hepatotoxicity and systemic toxicity. For this reason it should be performed by experienced hospitals.\(^{[89-91]}\)

Intravenously 5-FU and intra hepatic artery oxaliplatin are successfully used\(^{[92]}\) for unresectable CRC-LM. Best results concerning survival and response rates are obtained with floxuridine based HAI.\(^{[93]}\)

The comparison of OS between HAI therapy and systemic therapy alone (15.9 mo vs 12.4 mo) does not show any difference, however, there was a great response rate in favor of HAI (43% vs 18%).\(^{[94]}\)

In conclusion, HAI has interesting results; however it is a cumbersome method because it requires the implantation of an infusion pump.

**Chemoembolization**

Trans-arterial chemoembolization (TACE) is increasingly used for unresectable CRC-LM, improving survival and tumor response.\(^{[95]}\) TACE is indicated for unresectable CRC-LM as third line therapy, and allows the attainment of important palliative results.

The use of drug-eluting beads for TACE increases efficacy, while reducing adverse events due to systemic drug leakage or liver toxicity.\(^{[95-98]}\) The advantage of these beads is the direct delivery of toxic drugs inside the arterial capillary bed of the tumor, releasing the drug in a controlled manner: In this way the systemic exposure to toxic drugs is reduced, their local concentration is increased and a greater tissue necrosis than classic TACE with lipiodol is obtained.\(^{[99,100]}\)

The indication for TACE is presence of multinodular LM, absence of extra hepatic disease, refractory to systemic chemotherapy.\(^{[101]}\)

Recent reports show that TACE with irinotecan (DEBIRI) for the treatment of CRC-LM is effective, feasible and has limited side effects.\(^{[95-101]}\) Systemic chemotherapy (FOLFIIRI) is compared to DEBIRI for...
the therapy of refractory CRC-LM in some studies. This comparison shows that DEBIRI is statistically better than FOLFIRI in terms of OS, PFS, time to extra-hepatic progression, and quality of life[95].

The association of cetuximab and TACE with irinotecan is an improvement in the treatment of CRC-LM, because these drugs are efficacious and have acceptable, and not cumulative, toxicities[102].

The TACE methodology is constantly improving, in particular, the last innovation is the introduction of new embolics for drug delivery. Among the new types of microspheres there are polyethylene glycol (PEG) microspheres (LifePearls, Terumo), that are more resistant to stress and attrition. The advantages of these embolics are increased suspension time, better catheter deliverability and drug retention and release[103].

In a recent study we show the data of TACE with PEG embolics for the treatment of 20 cases of non resectable liver tumors and metastases from colorectal carcinoma, breast cancer and uveal melanoma. Irinotecan and doxorubicin are used for PLC and LM respectively. More than 80% of cases respond to TACE patients. We observe 63% of CR, and 37% PR. The chemoembolization procedure is well tolerated by all the patients with only mild or moderate adverse events. These results indicate that PEG embolics-TACE is effective and tolerable for the therapy of hepatic primary and metastatic cancer[103].

**Radioembolization**

In the last decade radioembolization (RE) with Yttrium 90 (Y90) has been widely used for the treatment of CRC-LM that are refractory to chemotherapy[104]. Objective tumor response rates of RE are 33%-48% in second line[105,106] and 10%-48% in third line[107,108]. Survival and progression free survival are also improved after RE application as third line[100]. RE with Y90 has, however, a low recommendation in the last ESMO guidelines[110].

In theory, the treatment decision is very challenging for CRC-LM patients that are refractory to chemotherapy. Several patients are unfit and have a biologically unfavorable progression often associated to comorbidities. Palliative care with chemo- or radio-embolization is indicated in these cases, in order to avoid too aggressive therapies.

**MULTIDISPLINARY TEAM**

The involvement of a multidisciplinary approach should be promoted in order to obtain the best CRC-LM management and outcomes, and to reduce peri-operative morbidity and mortality, prolonging OS and rising resection rates[110,111].

For this reason, the multidisciplinary team management of CRC-LM is growing in most Western countries[112]. The team includes different types of specialists including: Liver surgeons; interventional radiologists specialized in hepatobiliary disease; an oncologist; a pathologist; and a case manager nurse. They have to discuss each case to ensure resectability appropriateness and lead to downgrading wherever possible. The team should be consulted about the choice of chemotherapy combination and type of targeted agents and care to be used, timing of chemoholidays, and follow up.

Medical oncologists select the most active treatment for the shortest time combining chemotherapy to targeted drugs, in order to reduce tumor size without damaging the normal liver. The definition of the acceptable FRL should be performed by a radiologist and a liver surgeon. Repeating the resection is safe and effective, obtaining survival rates close to those after first resection[112,113]. Finally the case manager nurse or the practitioner are important in patient’s management, because they provide indications on the follow up and assistance.

**CONCLUSION**

Recent improvements of CRC-LM treatment allows the down-staging of several patients, resulting in increased number of patients cured or living with longer disease...
control. There is currently no agreement about the correct sequence of surgical resection of the primary cancer and metastatic disease, however, the neoadjuvant chemotherapy is widely accepted as up front treatment.

Surgical resection can be performed if the complete removal of cancer is achievable leaving an adequate FRL. The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.

The use of adjuvant chemotherapy is highly suggested, even if standardized protocols are still unclear. The use of adjuvant chemotherapy is widely accepted as up front treatment.
Treatment of colorectal cancer liver metastasis

Nitti D, Torri V, Elias D, O’Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougiere P. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized phase II trials. Ann Oncol 2008; 29: 4906–4911 [PMID: 18794541 DOI: 10.1093/annonc/dmn056]

Power DG, Kemény NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol 2010; 28: 2300-2309 [PMID: 20368552 DOI: 10.1200/JCO.2009.26.9340]

Brandi G, De Lorenzo S, Nanni M, Curti S, Ottone M, Dall’Olio FG, Barbera MA, Pantealeo MA, Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol 2016; 22: 519-533 [PMID: 26811604 DOI: 10.3748/wjg.v22.i2.519]

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer (version 2. 2016). [accessed 2016 Jan 24]. Available from: URL: www.nccn.org

Adam R, de Grammont A, Figuera J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougiere P, Rubbia-Brandt L, Sobrero A, Teh C, Tejpar S, Van Cutsem E, Vauthey JN, Pálhalmi L. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 2015; 41: 729-741 [PMID: 26417845 DOI: 10.1016/j.ctrv.2015.06.006]

Masi G, Loupakis F, Pollina L, Vaisle E, Cupini S, Ricci S, Brunetti IM, Ferraldereschi R, Nasi G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Formaro L, Andreuccetti M, Falcone A. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009; 249: 420-425 [PMID: 19247029 DOI: 10.1097/SLA.0b013e3181a9486f]

Giacchetti S, Izhakhi M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misser JL, Lévi F. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRI) followed by surgical resection. World J Gastroenterol 2010; 16: 1964-1970 [PMID: 19567451 DOI: 10.3748/wjg.v16.i17.1964]

Adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol 2009; 27: 1869-1874 [PMID: 19092689 DOI: 10.1200/JCO.2008.18.7729]

Guidelines in Oncology. Colon Cancer (version 2. 2016). [accessed 2016 Jan 24]. Available from: URL: www.nccn.org

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitelli S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of intensified fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFOXIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860 DOI: 10.1200/JCO.2006.09.0925]

Ychou M, Rivone M, Thezenas S, Quenet F, Delpero JR, Rebschung C, Letoublon C, Guimbaud R, Francois E, Ducreux M, Desseigne F, Fabre JM, Assenat E. A randomized phase II trial of intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not resectable locoregional metastases. The METHEP trial. Ann Oncol 2013; 24: 8429-8427 [PMID: 23955585 DOI: 10.1093/annonc/dmt249]

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore I, Cortesi E, Tonelli G, Ronzoni M, Spadi R, Zamboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1619 [PMID: 25377350 DOI: 10.1056/NEJMoa1403108]

Kabbabinar FF, Schulz J, McCleod M, Patel T, Hammad JI, Hecht JR, Mass R, Perrou R, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 1961-1968 [PMID: 16026054 DOI: 10.1200/JCO.2004.02.5721]
Fiorentini G et al. Treatment of colorectal cancer liver metastasis

3697-3705 [PMID: 15738537 DOI: 10.1200/JCO.2005.05.112]

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffin S, Hohngren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbainvar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2010; 363: 1023-1034 [PMID: 20424839 DOI: 10.1056/NEJMoa0902357]

Bokemeyer C, Bordoneanu I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Streh C, Loos AH, Zabel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671 [PMID: 19114683 DOI: 10.1200/JCO.2008.20.8397]

Köhne CH, Poston G, Folprecht G, Ciardiello F, Ronga P, Beier F, Van Cutsem E. FOLFIRI plus cetuximab in patients with liver-resected or non-liver-resected RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study. Eur J Surg Oncol 2016; 42: 1540-1547 [PMID: 27575968 DOI: 10.1016/j.ejso.2016.05.038]

Garuti C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanela C, Vennarecci G, Mottolese M, Speredini I, Cognetti F. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010; 103: 1542-1547 [PMID: 20959822 DOI: 10.1038/sj.bjc.6605940]

Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Yu J. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver metastases. J Clin Oncol 2013; 31: 1931-1938 [PMID: 23569031 DOI: 10.1200/JCO.2012.44.8308]

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasan I, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrecht D, Kaplan R, Cheadle JP. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114 [PMID: 21641636 DOI: 10.1016/S0140-6736(11)60613-2]

Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pryhonen S, Sigurdsson F, Kure E, Ikdtal T, Skovlund E, Fokstuen T, Hansen F, Hofshi E, Birkenmeyer E, Johnsson A, Starkhammer H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (NORTEC) versus FOLFOX in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762 [PMID: 22473155 DOI: 10.1200/JCO.2011.38.0915]

Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler T, Fernerbo E, Gamelin E, Decosta L, Karthaus M. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2012; 138: 65-72 [PMID: 21960318 DOI: 10.1007/s00432-011-1061-6]

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barigel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasińska-Morawiec M, Śmakił M, Canon JL, Rother M, Williams R, Rong A, Wizorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034 [PMID: 24024839 DOI: 10.1056/NEJMoa1302357]

Peeters M, Tabernero J. Resection Rates and Survival in Patients with Wild-type KRAS Metastatic Colorectal Cancer and Liver Metastases: Data from the PRIME study. Markers in cancer - ASCO, EORTC and NCI meetings; 7-9 Nov 2013; Brussels, Belgium

Kruenger T, Bridgewater J, Chau I, Garcia-Alfonso P, Rivoire M, Mun W, Lasserre S, Hermann F, Waterkamp D, Adam R. Bevacizumab plus mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 2015; 26: 702-708 [PMID: 25538173 DOI: 10.1093/annonc/mdu580]
infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007; 25: 5649-5654 [PMID: 18065736 DOI: 10.1200/JCO.2007.12.1764

Fiorentini G, Albitori C, Tili M, Mulazzani L, Graziano F, Giordani P, Mambriani A, Montagnani F, Alessandroni P, Catalano V, Coschiera P. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intraoperative therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1395 [PMID: 22493375

Albitori C, Tili M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res 2010; 30: 7393-7395 [PMID: 17044403

Fiorentini G, Albitori C, Turrisi G, Del Conte A, Rossi S, Benea G, Giovanis P. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 2007; 21: 1085-1091 [PMID: 18210761

Albitori C, Fiorentini G, Muzzio PC, Pomerial F, Tili M, Dallara S, Benea G. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 2011; 31: 4581-4587 [PMID: 22199334

Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 2013; 33: 2077-2083 [PMID: 23645758

Lewis AL, Holden RR. DC Bead embolic drug-eluting bead: clinical application in the locoregional treatment of tumours. Expert Opin Drug Deliv 2011; 8: 153-169 [PMID: 21222553 DOI: 10.1517/1747247.2011.545388

Fiorentini G, Albitori C, Mulazzani L, Coschiera P, Catalano V, Rossi D, Giordani P, Ricci S. Chemoembolization in colorectal liver metastases: the rebirth. Anticancer Res 2014; 34: 575-584 [PMID: 24510896

Fiorentini G, Albitori C, Sarti D, Coschiera P, Tili M, Mulazzani L, Giordani P, Graziano F, Gonzalez AM, Marcos RG, Magnuz FG, Cantore M, Racci S, Catalano V, Mambriani A. Locoregional therapy and systemic cetuximab to treat colorectal liver metastasis. World J Gastroenterol 2015; 7: 54-54 [PMID: 26090075 DOI: 10.4251/wjgjs.v31.i.46

Albitori C, Carandina R, Sarti D, Mulazzani L, Catalano V, Felicioli A, Coschiera P, Fiorentini G. Hepatic Arterial Infusion of Polyethylene Glycol Drug-eluting Beads for Primary and Metastatic Liver Cancer Therapy. Anticancer Res 2016; 36: 3515-3521 [PMID: 27354617

Damm R, Seidensticker R, Ulrich G, Breier L, Steffen JG, Seidenschmitt M, Garibb P, Mohnke K, Pech M, Anthahar H, Rieke J. Y90 Radioembolization in chemo-refractory metastatic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. BMC Cancer 2016; 16: 509 [PMID: 27439702 DOI: 10.1186/s12885-016-2549-x

Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D, Little A, Bailey W, Liechtenstein M. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 2005; 5: 132 [PMID: 15225697 DOI: 10.1186/1471-2407-5-132

Bestler L, Metelting B, Pocock N, Saxena A, Chua TC, Morris DL. Radioembolisation with Yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases. J Med Imaging Radiat Oncol 2013; 57: 72-80 [PMID: 23374558 DOI: 10.1111/j.1754-9485.2012.02459.x

Cosimelli M, Golferri R, Cagol PP, Capuriano L, Sciuto R, Maini CH, Mascini R, Sperduti L, Piriz G, Diodoro MG, Perrone M, Giampalma E, Angelilli B, Fiore F,LASTORIA S, Bacchetti S, Gasperini D, Geatti O, Izzo F. Multi-phase centre II phase trial of yttrium-90 resin microspheres alone in unresectable, chemorefractory refractory colorectal liver metastases. Br J Cancer 2010; 103: 324-331 [PMID: 20628388 DOI: 10.1038/sj.bjc.6605770

Hendilis A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannooe J, De Keulekeire V, Verslype C, Defeyne V, Van Cutsem E, Delatte P, Delaunoit T, Personeni N, Paesmans M, Van Laethem JL.
Flamen P. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *J Clin Oncol* 2010; 28: 3687-3694 [PMID: 20567019 DOI: 10.1200/JCO.2010.28.5643]

109 Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J, Kettner E, Hildebrandt B, Dudeck O, Pech M, Amthauer H, Ricke J. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. *Cardiovasc Intervent Radiol* 2012; 35: 1066-1073 [PMID: 21800231 DOI: 10.1007/s00270-011-0234-7]

110 Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taieb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016; 27: 1386-1422 [PMID: 27380959 DOI: 10.1093/annonc/mdw235]

111 Lordan JT, Karanjia ND, Quiney N, Fawcett WJ, Worthington TR. A 10-year study of outcome following hepatic resection for colorectal liver metastases - The effect of evaluation in a multidisciplinary team setting. *Eur J Surg Oncol* 2009; 35: 302-306 [PMID: 18328668 DOI: 10.1016/j.ejso.2008.01.028]

112 Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks BW. Guidelines for resection of colorectal cancer liver metastases. *Gut* 2006; 55 Suppl 3: iii1-iii8 [PMID: 16835351 DOI: 10.1136/gut.2006.098053]

113 Ruiz-Tovar J, López Hervás P. Value of third metastasectomy of colorectal adenocarcinoma. *Clin Transl Oncol* 2007; 9: 56-58 [PMID: 17272232 DOI: 10.1007/s12094-007-0011-x]
